[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.205.109.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correction
July 7, 1999

Author Omitted

JAMA. 1999;282(1):29. doi:10.1001/jama.282.1.29

In the Editorial entitled "Understanding Parkinson Disease" published in the January 27, 1999, issue of THE JOURNAL (1999;281:376-378), selegiline was identified as an MAO type A inhibitor rather than a type B inhibitor. On page 377, the sentence should have read, "Selegiline is a monoamine oxidase type B inhibitor that limits the formation of free radicals derived from oxidation of dopamine, and application of this agent in clinical trials suggests an effect on disease progression consistent with a neuroprotective action.23-25"

×